Medtronic Vascular, Inc.

Jesus Casas

Adam Blakstvedt

Timothy H Robinson

Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain anti-inflammatory agents, are disclosed. The anti-inflammatory agents are selected from the group consisting of Sanglifehrin A, Sanglifehrin B, Sanglifehrin C, Sanglifehrin D, and pharmaceutically acceptable derivatives thereof. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the anti-inflammatory agent with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-anti-inflammatory agent blends are disclosed. Additionally, medical devices having a coating comprising at least one anti-inflammatory agent in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

Medical devices to prevent or inhibit restenosis

Methods, systems and devices for delivering a diagnostic or therapeutic treatment, substance or device to a target area located within the body of a human or animal subject. A tissue penetrating catheter is positioned within a body lumen near the target area. A hollow penetrator is then advanced from the tissue penetrating catheter and penetrated from the body lumen in which the penetrating catheter is positioned into tissue in the direction of the target area. Thereafter, an elongate optical device (e.g., an optically equipped guidewire or catheter) is advanced through the hollow penetrator and continues to advance through tissue, in the direction of the target area. The elongate optical device is connected to an optical processing device (e.g., a spectrometer) which provides optically determined data (e.g., spectral reflectance, pH, oxygen concentration, temperature) indicating when the elongate optical device has entered the target area. The elongate optical device is then used to facilitate delivery of a diagnostic or therapeutic modality, substance or device into the target area.

Growing community of inventors

Brooklyn Park, MN, United States of America

Jesus Casas